Member Info for crumbs

TNBC is still in the full dose mono cohort.... It is not in the combo because like Ovarian CPI are not standard care

'In the other monotherapy cancer cohorts, a total of eight patients have received full dose Modi-1

· One TNBC patient remains on trial with stable disease beyond 8 weeks

· One head and neck patient achieved a partial response and remains on study at week 37

Additionally, Scancell has recruited a fourth cohort of three patients receiving full dose Modi-1 in combination with the checkpoint inhibitor nivolumab. Subject to a safety committee review meeting scheduled to take place in August, this cohort will be expanded to 21 patients in both head and neck and renal cancer. Preliminary topline data from these cohorts is expected to be reported in 2024.'

Also when she talks about the Antibody that is under evaluation she says 'They look at the Anitbody for 6 months and decide does it work with their technology' So that to me sounds like CAR T (v exciting)

And then there is another company that will probably be one of the original companies possibly I'd say SeaGen

Violin I think you are misunderstanding ... She is talking about the targets which includes CPI as standard care which are head and neck and renal...

I don't mind is Wednesday wants to be great either :)

Is that the sound of stop losses popping ....

Also, the proactive as we know are all questions about points Scancell want to get across... So the GenMab question is a reassuring one... they are saying that the deal is still very much alive with GenMab giving all indications of developing the target so yes further milestone payments may well be expected

NASDAQ is only being looked at with clear clinical success behind it ... so it is not happening anytime soon, probably 2025 at the earliest...

Everything about Mkango is slow :)))

LWHL the clue is in the RNS:

'5. Date on which the threshold was crossed or reached: 13/02/2023'

Day of the placing ...

Something I wonder is I'm convinced Lindy is very clingy with her IP which of course on one hand is good she ain't for the low deal giveaway but on the other hand ne deal/s no progress Well now the Modi 1 data is yes still very early but showing pattern... In Ovarian target at least has her thinking changed a bit there ... for instance would she now be happy to do a Modi-! Ovarian Target deal with a CPI player for a combo trial .... That's something I'd like to ask amongst many other questions... and indeed is anyone actually seeking those deals out! Well, that shall be the job of the incoming but goodness they should already be always doing that...

I think on that Invetor forum thing we can ask for a meeting. something like that lol

Certainly, I'm sure there are tons of questions... This company was never ever supposed to be going to be doing a PH3 trial now they fancy doing 2???? what ....

The bussiness manager arrives in Sept too... think we need them.... be interesting to see who that 'difficult' hire is

There is an element of oh god the shareholders as in us the Pi's about today like you know we are an afterthought in everything.. including Lindy, at last, does a Proactive but the best time for that would have been the day of GenMab deal.... anyways it does look like Cossery is making his mark hurrah... that Investor Meeting presentation thing they have joined looks interesting too...

The thing is the tin is not getting rattled this year which I for one thought it would be... GenMab payments could come anytime seeing as they are still very happy with their mAb 2 other potential deals in the offing... and well... everything is really up for doing a deal isn't it....Meaning there is a chance the tin won't even need to be rattled but for now... back to the waiting game and sure.. SP won't get too excited although I think that Sept conference will cause some action

She did say if the clincal data continued to look really exciting and they need to move into registration studies funds would be needed for that... well not being funny but yeah that is a very good reason for raising funds and a good reason for being a part of that raise :)

They'll be shaking the assets right in front of BioNTech and indeed Genentech at that conference where they are both in attendance and indeed through CIMT Mrs. BioNTech is part of the Scientific planning committee

Oh I don't mean in anyway that the 44,% isn't of significance...And the whole design of this trial is to find where Modi 1 will perform best..

That it looks as though Modi 1 can induce an immune response in that target in a significant % of patients means there is potential to improve that either and or with other modi's CPIs or indeed other therapeutics ....By game changer I meant Modi 1 destroying tumors in that target....it's one for team Scancell science to work on and it could well already be enough to attract a CPI player to try a combo trial .... Trial still early days...It's just that probably toughest of all targets recruited fastest...again the reason for that is because there isn't anything else

No that's TCR ..CAR T is for mAbs remember they employed a member of team science to work on CAR T potential...must have paid off ,well will if there is a deal on that....so many strings to the bow! Glad that SCIB1 has reappeared so nicely....pity Modi 1s potency in that Ovarian cohort is not by itself game changer but still potential there...there is a reason that cohort is fully recruited and it's a grim one.... Anyways very happy to have an update and makes comfortable with my holding and nibbles 🙂

Immuobody delivered by pharmajet to me is indeed the dark horse it's just such a good opportunity for a pharma to make a move onto they pretty much guaranteed immune response results.... with all the other added pluses

Lindy obviously believes modi1 is heating up that tumor if she thinks a CPI could be introduced to improve that result it certainly will be a target the CPI players would like an in on which they have failed so far with

Well yeah :) anyways looks like we only need to wait till 7am tomorrow...So heres hoping